3rd Annual Pharma Pricing & Reimbursement Forum 2014

3rd Annual Pharma Pricing & Reimbursement Forum 2014

20-03-2014 - 21-03-2014 Vienna, Austria

The pharma industry has recently been facing increasing pressure from governmental and private stakeholders, such as patients, physicians and public payers as well.

The pharma industry has recently been facing increasing pressure from governmental and private stakeholders, such as patients, physicians and public payers as well.

The increasing costs of today’s healthcare environment and austerity issues place a big burden on pharma companies.

Balancing the price successfully while meeting economic and social requirements is the key to reach the planned number of potential patients. A well-planned and strong market access strategy is getting into the focus-point.

The event will highlight:

  • The pan-European situation of pharma industry
  • Importance of cost-containment and risk-sharing with austerity striking the whole European economy
  • The so-called 4th hurdle of P&R, latest developments
  • P&R as the cornerstone of future success yet at the earliest stages of market access
  • How to handle the growing HTA say in P&R?
  • Reveal of newest Pharma Policies and Updates recent regulations affect market access
  • Pharmacists’ view
  • P& R strategies of the Big Five, influence on each other’s market
  • Germany’s 2-year experience with AMNOG
  • Value-Based Pricing introduced in the United Kingdom; VBP plans and regulations
  • Italy under construction; Saying goodbye to AIFA-system?
  • Spain’s transparency and monetary issues
  • French ITR system expectations
  • International problems of innovating; biosimilars, lags in pharma industry
  • Oncology, wasting governmental budget or a branch of pharma industry to prosper?
  • Newcomers to affect EU pricing; Russia and Croatia through P&R eyes

Who Should Attend

Pharmaceutical companies, payers and policy makers, non-industry stakeholders: Senior Vice Presidents, Vice Presidents, Heads, Directors, Senior managers, managers of: Pricing and Reimbursement, Market Access, Commercial Pricing, Pricing Strategists, Health Economics, Outcome Research, Regulatory Affairs, Governmental Affairs, Public Affairs, Health Policy, Health Outcome, HTA, Public Policy, Governmental and Regulatory Bodies.

 

Back to top